Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 5, 2024

Theratechnologies to license Ionis’ RNA-targeted therapies in Canada

Theratechnologies has entered into a licensing agreement with Ionis Pharmaceuticals to acquire exclusive Canadian rights for two investigational RNA-targeted medicines, olezarsen and donidalorsen.

The agreement involves Ionis’ investigational RNA-targeted medicines, olezarsen and donidalorsen. Credit: digitale.de on Unsplash.